Zobrazeno 1 - 3
of 3
pro vyhledávání: '"CYP2D6, cytochrome P450 2D6"'
Monitoring Plasmodium vivax resistance to antimalarials: Persisting challenges and future directions
Autor:
Simone Ladeia-Andrade, Rodrigo M. Corder, Marcelo U. Ferreira, Gabriel W. Rangel, Igor Cavallini Johansen, Taís Nóbrega de Sousa, José Pedro Gil
Publikováno v:
International Journal for Parasitology: Drugs and Drug Resistance, Vol 15, Iss, Pp 9-24 (2021)
International Journal for Parasitology: Drugs and Drug Resistance
Repositório Institucional da USP (Biblioteca Digital da Produção Intelectual)
Universidade de São Paulo (USP)
instacron:USP
International Journal for Parasitology: Drugs and Drug Resistance
Repositório Institucional da USP (Biblioteca Digital da Produção Intelectual)
Universidade de São Paulo (USP)
instacron:USP
Emerging antimalarial drug resistance may undermine current efforts to control and eliminate Plasmodium vivax, the most geographically widespread yet neglected human malaria parasite. Endemic countries are expected to assess regularly the therapeutic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0e5ae265fa9864da475e8994bd43548
http://www.sciencedirect.com/science/article/pii/S221132072030049X
http://www.sciencedirect.com/science/article/pii/S221132072030049X
Autor:
Guilherme S. Lopes, Ye Zhu, Suzette J. Bielinski, Bijan J. Borah, Ann M. Moyer, Richard M. Weinshilboum, Nicholas B. Larson, Jennifer L. St. Sauver, Liewei Wang, Janet E. Olson
Publikováno v:
Mayo Clinic Proceedings: Innovations, Quality & Outcomes
Mayo Clinic Proceedings: Innovations, Quality & Outcomes, Vol 5, Iss 1, Pp 35-45 (2021)
Mayo Clinic Proceedings: Innovations, Quality & Outcomes, Vol 5, Iss 1, Pp 35-45 (2021)
Objective To assess the potential impact of Pharmacogenomic (PGx) variation in cytochrome P450 2D6 (CYP2D6) enzyme function, using loss in quality-adjusted life years (QALYs) associated with treatment problems, and the willingness to pay to avoid tre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a9a4191057ac7f23fa8b5a86914cea3
http://europepmc.org/articles/PMC7930862
http://europepmc.org/articles/PMC7930862
Autor:
Zhu Y; Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN.; Division of Health Care Policy and Research, Department of Health Sciences Research, Mayo Clinic, Rochester, MN., Lopes GS; Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, MN.; Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN., Bielinski SJ; Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, MN., Borah BJ; Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN.; Division of Health Care Policy and Research, Department of Health Sciences Research, Mayo Clinic, Rochester, MN., Larson NB; Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN., Moyer AM; Division of Clinical Biochemistry & Immunology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN., Olson JE; Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, MN., Wang L; Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN., Weinshilboum R; Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN., St Sauver JL; Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, MN.
Publikováno v:
Mayo Clinic proceedings. Innovations, quality & outcomes [Mayo Clin Proc Innov Qual Outcomes] 2021 Jan 13; Vol. 5 (1), pp. 35-45. Date of Electronic Publication: 2021 Jan 13 (Print Publication: 2021).